CHICAGO--(BUSINESS WIRE)--CANCIDAS® (caspofungin acetate) had a safety and efficacy profile generally similar to AmBisome® (liposomal amphotericin B or L-AmB) in a clinical study involving its investigational use for pediatric empirical therapy against suspected invasive fungal infections (IFI) in patients two to 17 years of age with persistent fever and neutropenia. L-AmB is regarded as a standard treatment option against IFI; and the use of CANCIDAS in pediatric patients is investigational. These results were presented today at the American Society for Microbiology’s 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
